- Home
- MNKD
MNKD
MannKind Corporation
as 10-07-2025 3:29pm EST
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | DANBURY |
| Market Cap: | 1.7B | IPO Year: | 2004 |
| Target Price: | $10.80 | AVG Volume (30 days): | 3.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.11 | EPS Growth: | 149.32 |
| 52 Week Low/High: | $3.38 - $7.63 | Next Earning Date: | 11-06-2025 |
| Revenue: | $301,736,000 | Revenue Growth: | 21.48% |
| Revenue Growth (this year): | 16.36% | Revenue Growth (next year): | 20.34% |
Stock Insider Trading Activity of MannKind Corporation (MNKD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tross Stuart A | MNKD | Chief People & Workpl Officer | Sep 16 '25 | Sell | $5.34 | 47,000 | $250,980.00 | 1,032,013 |
Latest MannKind Corporation News
MNKD Breaking Stock News: Dive into MNKD Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Does MannKind (NASDAQ:MNKD) Deserve A Spot On Your Watchlist?
Zacks
a month ago
Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?
Zacks
3 months ago
Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock?
Insider Monkey
3 months ago
Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating
Insider Monkey
3 months ago
MannKind (MNKD) Presents Pediatric Insulin Trial Data
GlobeNewswire
4 months ago
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
GlobeNewswire
4 months ago
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
GlobeNewswire
5 months ago
MannKind to Present at Upcoming Investor Conferences
Compare MNKD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNKD MannKind Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.